Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.82 USD | +0.71% | -1.40% | -51.38% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Low profitability weakens the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.38% | 18.79M | B- | ||
+16.59% | 44.44B | B- | ||
-10.62% | 37.68B | B | ||
+42.27% | 39.84B | A | ||
+29.92% | 31.46B | B | ||
-9.78% | 27.02B | C | ||
+12.34% | 26.29B | B- | ||
+41.53% | 13.8B | B+ | ||
+31.49% | 12.46B | C+ | ||
-7.40% | 11.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEIP Stock
- Ratings MEI Pharma, Inc.